KPV
Also known as: alpha-MSH(11-13), Lysine-Proline-Valine
KPV is a short tripeptide fragment related to alpha-MSH, studied in the laboratory for reported anti-inflammatory properties. It is a research peptide and is not approved for human use in Australia.
- Category
- Immune / Anti-inflammatory
- Reported half-life
- Not well established
- Common forms
- Lyophilised powder for reconstitution (research preparations)
- Research status
- A short alpha-MSH-derived peptide studied in laboratory and animal research; it is a research peptide and is not approved for human use in Australia.
- Last updated
- 21 June 2026
Claimed effects
The following effects are reported or claimed by users and in early research. They are not established medical facts and many are not supported by large human trials.
- Reported to have anti-inflammatory properties in laboratory studies
- Reported to be studied in relation to gut and skin inflammation models
- Reported to be associated with immune-modulating processes in research
How it is reported to work
KPV is the C-terminal tripeptide fragment of alpha-melanocyte-stimulating hormone (alpha-MSH) and is proposed to interact with inflammatory signalling pathways inside cells. These proposed mechanisms come largely from in vitro and animal research and should be regarded as preliminary rather than established for any human therapeutic use.
Background
KPV is a short tripeptide (lysine-proline-valine) corresponding to the C-terminal fragment of alpha-melanocyte-stimulating hormone (alpha-MSH). It is studied in the laboratory in connection with inflammation. This page is educational information, not medical advice, and the effects described below are reported claims, not established facts.
What the research shows
Most published research on KPV consists of laboratory and animal studies exploring anti-inflammatory activity, including in gut and skin models. These suggest possible roles, but the body of human evidence is limited and not translated into approved therapy.
| Evidence type | Status |
|---|---|
| Laboratory (in vitro) studies | Present |
| Animal studies | Present |
| Large human clinical trials | Limited |
| Australian approval | None |
What people use it for (reported)
Online, people report interest in KPV in connection with inflammation and gut or skin topics. These are anecdotal reports, not validated clinical outcomes, and nothing here should be read as encouragement to use it.
Things to be aware of
KPV is not approved for human use in Australia. Its safety profile in humans is not well understood, and grey-market preparations cannot be verified for purity or identity by sight. If you have an inflammatory or immune-related concern, the appropriate step is to speak with a qualified healthcare professional. This article does not recommend obtaining or using KPV. All effects described here remain reported claims, not established facts.
Reported positives & side effects
Compiled from research and community reports. These are reported outcomes, not guarantees or medical advice, individual experiences vary widely.
Reported positives
- Reported in research for anti-inflammatory activity
- Reported interest in gut-related and skin inflammation in studies
- Reported to be a tripeptide fragment of alpha-MSH studied without the tanning effect
- Reported anecdotally for general recovery and irritation
Common side effects
- Reported injection-site redness or irritation
- Reported mild localised discomfort
- Reported transient flushing
- Reported headache anecdotally
Rare / serious side effects
- Reported allergic or hypersensitivity-type reactions
- Reported gastrointestinal upset with oral preparations
- Reported unpredictable reactions from unverified grey-market product
Reported misuse & overdose risks
What has been reported to happen with overuse, excessive dosing, or long-term misuse of KPV. Listed so you can make an informed decision, not to suggest any use is safe.
- Reported self-dosing for unproven inflammatory or autoimmune conditions without oversight
- Reported dose escalation beyond any researched range seeking stronger effects
- Reported use of self-sourced product whose identity and purity cannot be confirmed
- Reported substitution for medically indicated treatment of inflammatory disease
Reported results timeline
Roughly how long people report it takes to notice effects. A general guide from reports, not a promise, and not advice. Reported onset is described over days to weeks, with no clinically established human timeline.
First effects
any reported subjective change within days
Noticeable change
reported anti-inflammatory or recovery sensations over weeks
Clear results
reported cumulative changes after extended use; not clinically established
Commonly reported dosing & protocol
Reported figures only, NOT a recommendation or dosing advice. These are numbers people report using, compiled for education so you can make an informed decision. We do not advise anyone to take KPV. Many peptides are not approved for human use in Australia. Speak to a qualified healthcare professional.
| Route | Reported as subcutaneous injection or oral capsule (research use) |
|---|---|
| Typical reported dose | Reported around 200-500 mcg per dose |
| Frequency | Reported once or twice daily in anecdotal accounts; no established schedule |
| Cycle length | No established cycle length; reported short courses of a few weeks anecdotally |
Reported reconstitution (mg → units)
For injected use, reported example: a 10 mg vial plus 5 mL bacteriostatic water gives 2 mg/mL. A reported 500 mcg (0.5 mg) dose is about 0.25 mL, which is roughly 25 units on a U-100 insulin syringe. Oral preparations are not reconstituted this way.
Work out the units for your vial → CalculatorCommonly reported as short daily courses, oral or injectable, over a few weeks; this is reported information, not advice.
Best used with / commonly stacked with
Combinations people report using together. Reported, not recommended, stacking can increase risks.
Reported together anecdotally for gut and tissue-repair interest
Reported together for combined immune and anti-inflammatory interest
Reported alongside it for interest in gut-barrier and inflammation
Safety notes
KPV is a research peptide and is not approved for human use in Australia. Its safety in humans is not well characterised, and grey-market product purity and identity cannot be verified by consumers. Anyone with an inflammatory or immune-related concern should consult a qualified healthcare professional rather than self-experiment.